In the SURMOUNT-5 trial, Tirzepatide achieved 20.2% weight loss versus 13.7% for Semaglutide at 72 weeks a 47% greater relative reduction
Orforglipron's lack of a liver signal provides hope that there is a chemical series that avoids it
If you draw too fast, you may create bubbles or draw air instead of solution
There is only one other FDA-approved treatment for MASH, a drug called Rezdiffra that stimulates thyroid receptors in the liver but does not cause weight loss
The rate of weight loss can vary based on factors such as individual metabolism, adherence to the prescribed diet, and exercise routine
This typically includes medical expenses (past and future), lost wages or earning capacity, pain and suffering, emotional distress, and in some cases, punitive damages